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C-type natriuretic peptide (CNP) activation of the guany-
lyl cyclase-linked natriuretic peptide receptor-B (NPR-B)
stimulates vasorelaxation and bone growth. Hormones
and phorbol esters (PMA) inhibit NPR-B in calcium- and
protein kinase C-dependent manners, respectively. Here,
we characterize the kinetic properties of NPR-B in mem-
branes from cells exposed to PMA, the calcium iono-
phore, ionomycin, or sphingosine-1-phosphate (S1P).
PMA and ionomycin primarily increased the Km  and
decreased the Vmax  of NPR-B for GTP, respectively,
whereas S1P caused modest changes in both parameters.
PMA and S1P treatment increased the EC50 for CNP acti-
vation by 8 and 3-fold, whereas ionomycin was ineffec-
tive. All three agents caused NPR-B dephosphorylation,
but the basis for the loss of phosphate differed between
treatments. In vitro phosphorylation of NPR-B in mem-
branes was markedly diminished by prior PMA or S1P
exposure, whereas ionomycin pretreatment had no effect.
The involvement of the known phosphorylated residues
in each process was tested with a mutant receptor contain-
ing glutamates substituted for these sites. While the effect
of PMA was lost on this receptor, the effects of S1P and
ionomycin were only partially blocked. Our data suggest
that the molecular bases for PMA- and calcium-dependent
inhibition of NPR-B are unique. The former results from
reduced phosphorylation of a known site and primarily
affects the affinity of NPR-B for CNP and GTP. The latter
is associated reductions in maximal velocities by a mech-
anism that does not involve inhibition of NPR-B phos-
phorylation and requires a process in addition to the
dephosphorylation of the known sites.
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